Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

Shares of yet an­oth­er NASH hope­ful are rock­et­ing north this morn­ing, with Tel Aviv-based Galmed post­ing news on its Phase IIb fat­ty liv­er dis­ease drug. Al­though the da­ta are ex­cit­ing some in­vestors, the re­sults were al­so dis­tinct­ly mixed, rais­ing some doubts about the sud­den en­thu­si­asm.

The com­pa­ny, which re­port­ed a flop for the roll­out of its last NASH tri­al, to­day re­port­ed top-line, 52-week re­sults from a glob­al study test­ing its drug Aram­chol in a high dose (600 mg) and low­er dose (400 mg), along­side a place­bo. The goal was to cut down liv­er fat, with the sec­ondary end­points shoot­ing for a re­duc­tion in scar­ring (fi­bro­sis) and NASH res­o­lu­tion. The low­er dose met the pri­ma­ry end­point, the com­pa­ny said, post­ing a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in liv­er fat vs. place­bo (p=0.0450). The high dose did not.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER